PXD058857 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | ARID1A-induced transcriptional reprogramming rewires signalling responses to drug treatment in melanoma |
Description | Proteomic study studying how ARID1A-mediated transcriptional rewiring drives resistance to MAPK inhibitors in melanoma by altering signalling pathways, immune interactions, and receptor dynamics, highlighting potential targets for combinatorial therapies. |
HostingRepository | PRIDE |
AnnounceDate | 2025-01-14 |
AnnouncementXML | Submission_2025-01-14_06:12:26.592.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Evangelia Petsalaki |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | phosphorylated residue |
Instrument | Orbitrap Exploris 480 |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2024-12-13 08:09:43 | ID requested | |
⏵ 1 | 2025-01-14 06:12:26 | announced | |
Publication List
Keyword List
submitter keyword: drug resistance,melanoma, phosphoproteomics |
Contact List
Evangelia Petsalaki |
contact affiliation | EMBL-EBI, Wellcome Genome Campus, CB10 1SD, Hinxton |
contact email | petsalaki@ebi.ac.uk |
lab head | |
Evangelia Petsalaki |
contact affiliation | EMBL-EBI |
contact email | petsalaki@ebi.ac.uk |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/01/PXD058857 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD058857
- Label: PRIDE project
- Name: ARID1A-induced transcriptional reprogramming rewires signalling responses to drug treatment in melanoma